NYU Winthrop Hospital currently utilizes three Institutional Review Boards to ensure that all research projects involving humans conducted at NYU Winthrop Hospital are performed in compliance with federal regulations. The three IRBs are NYU Winthrop Hospital IRB (WUH IRB), Western IRB (WIRB) and the National Cancer Institute Pediatric Central Institutional Review Board (Peds/CIRB). WIRB reviews all pharmaceutically sponsored outpatient Phase III and IV (post-marketing) studies and the NCI/Pediatric CIRB reviews Pilot, Phase II and III pediatric cancer cooperative group trials. The WUH IRB reviews all other research projects including; projects eligible for exempt status, expedited status, Phase I and II clinical trials, both inpatient and outpatient pharmaceutically sponsored trials, all studies involving investigational devices, investigator initiated trials, and federally sponsored projects. This site contains information for WUH IRB.
For more information on Western IRB and the NCI Central Institution Review Board, please visit the links below:
The NYU Winthrop Hospital Institutional Review Board (WUH IRB) is the body that is designated by the NYU Winthrop Hospital Executive Committee of the Medical Staff to review, approve the initiation of, and conduct continuing review of research involving human subjects. The primary purpose of the IRB is constituted in accordance with the code of Federal Regulations 21 CFR Part 50, 21 CFR Part 56 and 45 CFR Part 46. WUH IRB hereby gives assurance that it shall comply with applicable New York State Law (Article 24-A of the New York State Public Health Law).